Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
AssigneeClaragen, Inc.
InventorsAprile L. Pilon, Anil B. Mukherjee, Zhongjian Zhang
Life of this patent
Estimating the term…
Abstract
Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous fictional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.
Claims31
Method for inhibiting PLA2 enzymes in vivo in a mammal in need of such treatment, said method comprising the step of administering to said mammal an PLA2 inhibiting effective amount of rhUG.
Method for treating an inflammatory condition in vivo in a patient in need such treatment, said method comprising the step of administering to said patient an anti-inflammatory effective amount of rhUG.
Method for treating or preventing a fibrotic condition in a patient in need of such treatment, said method comprising the step of administering to a patient in need of such treatment a fibronectin binding effective amount of rhUG.
Method for treating or preventing an inflammatory or fibrotic condition characterized by a deficiency of endogenous functional UG, said method comprising the step of administering to a patient in need of such treatment a compensating amount of rhUG.
A pharmaceutical composition comprising a PLA2 inhibiting effective amount of rhUG in association with a pharmaceutical carrier or diluent.
A pharmaceutical composition comprising a fibronectin binding effective amount of rhUG in association with a pharmaceutical carrier or diluent.
Assay method for assaying for uterglobin fibronectin complex in a clinical sample, comprising:
- (a) contacting a clinical sample suspected of containing uteroglobin fibronectin complex with an antigen capture agent immobilized on an insoluble support;
- (b) introducing an antigen detection agent to said sample;
- and
- (c) detecting the presence of any said complex bound to said support.
Dependencies are inferred from the claim text.